![]() ![]() ![]() He received an undergraduate degree from Muhlenberg College. and Product Manager-Arthrotec & Cytotec at G.D. In his past career he occupied the position of Director at Innovation Development Institute, Inc., Divisional VP & General Manager-Immunology at Abbott Laboratories, Manager-Market Integration at Merck & Co., Inc., Chairman for Zyla Life Sciences LLC, Chairman, President & Chief Executive Officer of Horizon Pharma, Inc., Chairman at Exicure, Inc., President & Chief Executive Officer for Hyperion Therapeutics, Inc., President, Chief Executive Officer & Director at IDM Pharma, Inc., President & Chief Executive Officer of Horizon Therapeutics, Inc., Territory Manager at Wyeth Corp., Executive Vice President-Commercial Operations at NeoPharm, Inc. He is also Member of Illinois Innovation Council and on the board of 10 other companies. (both are subsidiaries of Horizon Therapeutics Plc). and President & Director at Viela Bio, Inc. Walbert is a businessperson who has been at the head of 10 different companies and holds the position of Chairman, President & Chief Executive Officer for Horizon Therapeutics Plc and President & Chief Executive Officer at Horizon Therapeutics USA, Inc. Grey received a Bachelor of Science in chemistry from the University of Nottingham in the United Kingdom.Biography Timothy P Walbert Chairman, President & Chief Executive Officer and Mirati Therapeutics Inc., both public biotechnology companies. ![]() Grey also serves on the boards of directors of BioMarin Pharmaceutical Inc. and Glaxo Holdings plc, culminating in his position as vice president, corporate development and director of international licensing. Before these, Grey served in various roles with Glaxo Inc. in 2001) and president of BioChem Therapeutic Inc. (sold to Eli Lilly and Company in 2008), president and chief executive officer of Trega Biosciences Inc. He has 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals Inc. From February 2011 to June 2014, Grey served as president and chief executive officer of Lumena Pharmaceuticals Inc., a biotechnology company, which was acquired by Shire plc in June 2014. Grey served from October 2015 to January 2017 as the president and chief executive officer of Amplyx, from September 2014 to December 2017 as chairman and chief executive officer of Reneo and from May 2019 until April 2020 as executive chairman of Curzion Pharmaceuticals Inc., a private pharmaceutical company. He has also served as a venture partner at Pappas Ventures since January 2010. Camardo served as Executive Vice President and Head. He has served as executive chairman of Spruce Biosciences Inc., a public biotechnology company, since April 2017 Amplyx Pharmaceuticals Inc., a private pharmaceutical company, since January 2017 Reneo Pharmaceuticals Inc., a private pharmaceutical company, since December 2017 and as chairman of Plexium Inc., a private biotechnology company, since August 2020. Camardo joined Athersys in February 2022 as our Chief Executive Officer. Before that he served as chief executive officer of Mirum from the company’s inception in March 2018. Grey has served as chairman of the board of directors of Mirum Pharmaceuticals Inc., a public biotechnology company, since January 2020, and as executive chairman from March 2019 to December 2019. (Tim) (Horizon Pharma 201003 CEO before IDM Pharma CEO before NeoPharm +. Michael Grey has served on the board of directors since September 2011 and as lead independent director of the company since August 2012. Biotechnology company Amgen has agreed to pay 27.8 billion to buy Horizon Therapeutics throwing into question the future of Horizon’s sprawling Deerfield offices. Horizon Pharma plc Product, Industry, pharmaceutical Person, Walbert, Timothy P. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |